NASDAQ:ARDX - Ardelyx Stock Price, Forecast & News

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARDX shares have decreased by 3.7% and is now trading at $5.76. View which stocks have been mosted impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ardelyx.

Ardelyx is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Ardelyx.

Ardelyx Inc (NASDAQ:ARDX) issued its quarterly earnings results on Friday, March, 6th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.06. The biopharmaceutical company earned $2.25 million during the quarter, compared to analysts' expectations of $0.70 million. View Ardelyx's earnings history.

5 Wall Street analysts have issued 1 year price objectives for Ardelyx's stock. Their forecasts range from $9.00 to $15.00. On average, they expect Ardelyx's stock price to reach $12.00 in the next year. This suggests a possible upside of 108.3% from the stock's current price. View analysts' price targets for Ardelyx.

Headlines about ARDX stock have trended very negative on Friday, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ardelyx earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutArdelyx.

Some companies that are related to Ardelyx include SAGE Therapeutics (SAGE), Akcea Therapeutics (AKCA), Theravance Biopharma (TBPH), Corcept Therapeutics (CORT), Insmed (INSM), Karyopharm Therapeutics (KPTI), CytoDyn (CYDY), Constellation Pharmaceuticals (CNST), Dicerna Pharmaceuticals (DRNA), Innoviva (INVA), Ligand Pharmaceuticals (LGND), I-Mab (ARQT), ZEALAND PHARMA/S (ZEAL), Zogenix (ZGNX) and Heron Therapeutics (HRTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP), BioCryst Pharmaceuticals (BCRX), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), ImmunoGen (IMGN), SCYNEXIS (SCYX) and Gilead Sciences (GILD).

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARDX stock can currently be purchased for approximately $5.76.

Ardelyx has a market capitalization of $379.01 million and generates $5.28 million in revenue each year. The biopharmaceutical company earns $-94,940,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Ardelyx employs 86 workers across the globe. View additional information about Ardelyx.

The official website for Ardelyx is http://www.ardelyx.com/.

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]